GCG and fatty liver disease: The ability of KDT501 to stimulate incretin secretion can account for the enhancement of glucose homeostasis in the absence of weight loss, but the loss of fat mass seen with sustained treatment undoubtedly contributed to the ensuing improvement of other features of metabolic syndrome, including dyslipidemia, hepatic steatosis, and chronic inflammation.